AVBP - CIK 0001868279
The table below shows ArriVent BioPharma, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$160.59M | -$70.21M | -$55.84M |
| Capital expenditure | - | - | - |
| Investing cash flow | -$71.23M | -$192.47M | - |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $203.06M | $186.58M | $42.86M |
ArriVent BioPharma, Inc. reported operating cash flow of -$160.59M for fiscal year 2025. That is down 128.7% from -$70.21M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.